SEC Form 4 · accession 0001209191-19-003070
bluebird bio, Inc. · BLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Davidson
Officer — Chief Medical Officer
Period of report
Jan 7, 2019
Accepted (ET)
Jan 9, 2019 · 4:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 7, 2019 | S | 1,748 | $113.2893 | D | 23,157 | D | |
| Common StockF1,F3 | Jan 7, 2019 | S | 916 | $114.3057 | D | 22,241 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.
- F2The range in prices for the transaction reported on this line was $112.73 to $113.70. The average weighted price was $113.2893. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The range in prices for the transaction reported on this line was $113.78 to $114.72. The average weighted price was $114.3057. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.